Cargando…
MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer
Background: Cervical cancer is the fourth most common cancer among females worldwide. Identifying peptide patterns discriminating healthy individuals from those with diseases has gained interest in the early detection of cancers. Our study aimed to determine signature peptide patterns for cervical c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452062/ https://www.ncbi.nlm.nih.gov/pubmed/37626823 http://dx.doi.org/10.3390/biomedicines11082327 |
_version_ | 1785095573680947200 |
---|---|
author | Rungkamoltip, Phetploy Roytrakul, Sittiruk Navakanitworakul, Raphatphorn |
author_facet | Rungkamoltip, Phetploy Roytrakul, Sittiruk Navakanitworakul, Raphatphorn |
author_sort | Rungkamoltip, Phetploy |
collection | PubMed |
description | Background: Cervical cancer is the fourth most common cancer among females worldwide. Identifying peptide patterns discriminating healthy individuals from those with diseases has gained interest in the early detection of cancers. Our study aimed to determine signature peptide patterns for cervical cancer screening. Methods: Our study focused on the serum peptidome analysis of 83 healthy women and 139 patients with cervical cancer. All spectra derived from matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were analyzed using FlexAnalysis 3.0 and ClinProTools 2.2 software. Results: In the mass range of 1000–10,000 Da, the total average spectra were represented as the signature pattern. Principal component analysis showed that all the groups were separately distributed. Furthermore, the peaks at m/z 1466.91, 1898.01, 3159.09, and 4299.40 significantly differed among the investigated groups (Wilcoxon/Kruskal–Wallis test and ANOVA, p < 0.001). Conclusions: Laboratory-based rapid mass spectrometry showed that serum peptidome patterns could serve as diagnostic tools for diagnosing cervical cancer; however, verification through larger cohorts and association with clinical data are required, and the use of externally validated samples, such as patients with other types of cancers, should be investigated to validate the specific peptide patterns. |
format | Online Article Text |
id | pubmed-10452062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104520622023-08-26 MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer Rungkamoltip, Phetploy Roytrakul, Sittiruk Navakanitworakul, Raphatphorn Biomedicines Article Background: Cervical cancer is the fourth most common cancer among females worldwide. Identifying peptide patterns discriminating healthy individuals from those with diseases has gained interest in the early detection of cancers. Our study aimed to determine signature peptide patterns for cervical cancer screening. Methods: Our study focused on the serum peptidome analysis of 83 healthy women and 139 patients with cervical cancer. All spectra derived from matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were analyzed using FlexAnalysis 3.0 and ClinProTools 2.2 software. Results: In the mass range of 1000–10,000 Da, the total average spectra were represented as the signature pattern. Principal component analysis showed that all the groups were separately distributed. Furthermore, the peaks at m/z 1466.91, 1898.01, 3159.09, and 4299.40 significantly differed among the investigated groups (Wilcoxon/Kruskal–Wallis test and ANOVA, p < 0.001). Conclusions: Laboratory-based rapid mass spectrometry showed that serum peptidome patterns could serve as diagnostic tools for diagnosing cervical cancer; however, verification through larger cohorts and association with clinical data are required, and the use of externally validated samples, such as patients with other types of cancers, should be investigated to validate the specific peptide patterns. MDPI 2023-08-21 /pmc/articles/PMC10452062/ /pubmed/37626823 http://dx.doi.org/10.3390/biomedicines11082327 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rungkamoltip, Phetploy Roytrakul, Sittiruk Navakanitworakul, Raphatphorn MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer |
title | MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer |
title_full | MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer |
title_fullStr | MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer |
title_full_unstemmed | MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer |
title_short | MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer |
title_sort | maldi-tof ms analysis of serum peptidome patterns in cervical cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452062/ https://www.ncbi.nlm.nih.gov/pubmed/37626823 http://dx.doi.org/10.3390/biomedicines11082327 |
work_keys_str_mv | AT rungkamoltipphetploy malditofmsanalysisofserumpeptidomepatternsincervicalcancer AT roytrakulsittiruk malditofmsanalysisofserumpeptidomepatternsincervicalcancer AT navakanitworakulraphatphorn malditofmsanalysisofserumpeptidomepatternsincervicalcancer |